6533b7dcfe1ef96bd12720a8

RESEARCH PRODUCT

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience

Valerio GallottaSalvatore Gueli AllettiGiovanni ScambiaAlfredo ErcoliCamilla NeroGabriella FerrandinaFrancesco FanfaniAnna FagottiVito ChianteraBarbara Costantini

subject

Secondary cytoreductionmedicine.medical_treatmentTissue AdhesionsPostoperative ComplicationsLaparotomyLaparoscopyOvarian Neoplasmsmedicine.diagnostic_testMedicine (all)Middle Agedovarian cancerChemotherapy AdjuvantLymphatic MetastasisFemaleAdult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy; Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laparoscopy; Laparotomy; Length of Stay; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Monitoring; Intraoperative; Neoplasm Recurrence; Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Postoperative Complications; Retrospective Studies; Tissue AdhesionsAdultmedicine.medical_specialtyRecurrent ovarian cancer; Laparoscopy; Secondary cytoreductionOperative TimeAntineoplastic AgentsDisease-Free SurvivalLaparoscopicMonitoring IntraoperativeInternal medicineCarcinomamedicineHumansAgedNeoplasm StagingRetrospective StudiesLaparotomybusiness.industryGeneral surgeryCarcinomaRetrospective cohort studyLength of StayHepatologymedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIARecurrent Ovarian CancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalRecurrent ovarian cancerOvarian cancerbusinessFollow-Up StudiesAbdominal surgery

description

Background: Optimally, secondary cytoreduction is acknowledged as a valid option in terms of oncologic outcome for patients with platinum-sensitive recurrent ovarian cancer. In cases of localized relapse, a laparoscopic approach has been attempted at various institutions, but studies on its role for this subset of patients still are limited. This report describes the authors' experience using laparoscopic secondary cytoreduction for patients with localized recurrent ovarian cancer. The results from a retrospective analysis of a prospective case series are reported. Methods: Between October 2011 and May 2013, 29 patients with localized recurrent ovarian cancer were selected for a laparoscopic cytoreduction. Two conversions to laparotomy occurred. The analyzed outcome variables included stage and site of disease, type of surgical procedure, operative time, blood loss, length of hospital stay, complications, and oncologic outcome. Results: The median operating time was 188 min. The median estimated blood loss was 150 mL, and the median hospital stay was 4 days. Complete debulking was achieved for 96.2 % of the patients. No intraoperative complications occurred, and postoperative complications were noted in only one patient. The median disease-free survival time was 14 months. Conclusions: For selected patients, laparoscopy is a feasible and safe approach to optimal cytoreduction for patients with localized recurrent ovarian cancer. © 2014 Springer Science+Business Media.

10.1007/s00464-013-3390-9http://hdl.handle.net/11391/1194486